Drugs / Gobik
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03891758 | Apr → Sep 2019 | bacterial meningitis, diphtheria, pertussis, poliomyelitis +1 | Tanabe Pharma Corporation | Completed | Met primary |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-03-15 | Tanabe Pharma Corporation | Launch of "GOBIK Aqueous Suspension Syringes", Pertussis, Diphtheria, Tetanus, Inactivated Polio and Hib Combined Vaccine tanabe-pharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gobik | “A single-agent Gobik, the first DPT-IPV-Hib pentavalent vaccine approved in Japan” PMID 38582691 ↗ Apr 2024 |
| Modality | Vaccine | “a pentavalent vaccine Gobik (DPT-IPV-Haemophilus influenzae type b [Hib])” PMID 38582691 ↗ Apr 2024 |